Bicocca Open Archive

Logo unimib boa
ALBERTI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.706
EU - Europa 6.598
AS - Asia 3.257
SA - Sud America 29
OC - Oceania 28
AF - Africa 24
Continente sconosciuto - Info sul continente non disponibili 15
Totale 22.657
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.505
IT - Italia 1.629
SG - Singapore 1.238
DE - Germania 1.126
CN - Cina 1.112
SE - Svezia 901
IE - Irlanda 878
RU - Federazione Russa 715
UA - Ucraina 342
HK - Hong Kong 339
GB - Regno Unito 309
CA - Canada 188
VN - Vietnam 129
IN - India 124
FI - Finlandia 123
DK - Danimarca 118
FR - Francia 113
AT - Austria 105
TR - Turchia 95
JP - Giappone 84
KR - Corea 48
BE - Belgio 45
NL - Olanda 45
ES - Italia 39
AU - Australia 26
ID - Indonesia 25
TW - Taiwan 15
CH - Svizzera 13
EU - Europa 13
IR - Iran 11
BR - Brasile 10
GR - Grecia 10
PL - Polonia 10
RO - Romania 10
BG - Bulgaria 9
HR - Croazia 9
PK - Pakistan 9
CZ - Repubblica Ceca 8
PT - Portogallo 8
EG - Egitto 7
NO - Norvegia 7
AR - Argentina 6
GT - Guatemala 6
PE - Perù 6
SI - Slovenia 6
SC - Seychelles 5
TH - Thailandia 5
ZA - Sudafrica 5
LU - Lussemburgo 4
MX - Messico 4
MY - Malesia 4
SA - Arabia Saudita 4
CL - Cile 3
HU - Ungheria 3
IL - Israele 3
LV - Lettonia 3
RS - Serbia 3
AE - Emirati Arabi Uniti 2
BH - Bahrain 2
CO - Colombia 2
EC - Ecuador 2
ET - Etiopia 2
IS - Islanda 2
JM - Giamaica 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
TN - Tunisia 2
UG - Uganda 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BF - Burkina Faso 1
GE - Georgia 1
IQ - Iraq 1
KW - Kuwait 1
LB - Libano 1
LI - Liechtenstein 1
LT - Lituania 1
MM - Myanmar 1
PA - Panama 1
PH - Filippine 1
Totale 22.657
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.158
Singapore 1.046
Fairfield 860
Dublin 852
Woodbridge 831
Wilmington 790
Chandler 718
Frankfurt am Main 683
Ashburn 591
Milan 580
Houston 531
Dearborn 505
Santa Clara 392
New York 366
Jacksonville 364
Seattle 364
Hong Kong 332
Princeton 330
Cambridge 290
Nanjing 206
Shanghai 141
Boardman 131
Guangzhou 115
Vienna 101
Lawrence 94
Beijing 89
Altamura 75
Dong Ket 69
Lachine 55
Nanchang 55
San Diego 53
Andover 52
Rome 52
Shenyang 51
Chicago 49
Toronto 48
Helsinki 46
Hebei 40
Hangzhou 38
Tianjin 38
Los Angeles 37
Brussels 35
Carate Brianza 35
Pune 35
Ottawa 34
Jinan 33
Mountain View 32
London 31
Melzo 31
Tokyo 30
Changsha 29
Norwalk 28
Kunming 27
Falls Church 25
Jakarta 25
Edmonton 24
Zhengzhou 22
Mainz 21
Shangdi 21
Florence 20
Fremont 20
Jiaxing 19
Dallas 18
Lissone 18
Lappeenranta 17
Washington 17
Sacramento 16
Romola 15
Turin 15
Bologna 14
Ningbo 14
Sesto San Giovanni 14
Yuseong-gu 14
Athens 13
Hefei 12
Kiev 12
Baltimore 11
Brescia 11
Salt Lake City 11
Shenzhen 11
Bari 10
Chongqing 10
Kocaeli 10
Monza 10
Naples 10
Amsterdam 9
Canazei 9
Chengdu 9
Paris 9
Trieste 9
Bergamo 8
Cagliari 8
Mumbai 8
Munich 8
Redmond 8
Sydney 8
Codroipo 7
Como 7
Fort Wayne 7
Granada 7
Totale 16.219
Salva come PNG Salva come JPEG
Nome #
Nelarabine-Induced Neurotoxicity: Reversible Damage not only on Peripheral Nerves 337
Translational Approach to Oxaliplatin Induced Peripheral Neurotoxicity - Neurophysiology: the Link between Bed and Bench "side" 331
Peripheral neuropathy induced by microtubule-targeted chemotherapies: Insights into acute injury and long-term recovery 303
Evaluation of the Profile and Mechanism of Neurotoxicity of Water-Soluble [Cu(P)4]PF6 and [Au(P)4]PF6 (P = thp or PTA) Anticancer Complexes 302
High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats 297
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics 292
Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings 282
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 251
Role of Organic Transporters 1 and 2 in Cisplatin mediated neurotoxicity 235
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve 233
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 230
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 220
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings 218
Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity 217
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis 216
Guillain-Barré syndrome related to COVID-19 infection 215
Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity 207
Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy 204
Molsidomine reduces the severity of Vincristine-induced peripheral neurotoxicity in rats 204
Neuronopathies and polyneuropathies: a ready to use translational neurophysiological protocol in rodent models 199
The validation of neuroactive drug selection based on combinatorial screening in bortezomib-induced neurotoxicity models. 196
Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity 195
Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data 193
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer 188
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 185
Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy 185
Study of perpheral neurotoxicity of different doses of oxaliplatin in cd1 mice 183
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients 178
Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNoms study 178
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 178
Nerve Excitability Testing to Unravel Chemotherapy Induced Peripheral Neurotoxicity (CIPN) Pathogenesis: Altered Axonal Excitability as a Possible Pivotal Event Related to Platinum Compounds and Taxanes 177
Assessment of oxaliplatin-induced peripheral neurotoxicity with different treatment schedules 177
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 171
Sensory-motor paclitaxel polyneuropathy characterization in a rat model 170
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 169
Chemotherapy-induced neuropathy 168
Molsidomide provides neuroprotection against vincristine-induced peripheral neurotoxicity 167
Severe, reversible nelarabine-induced neuropathy and myelopathy 165
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 163
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 158
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study 157
Chemotherapy induced peripheral neurotoxicity: Six essential articles for effective future research 157
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial 155
Topiramate possible double efficacy profile: Oxaliplatin-induced peripheral neurotoxicity prevention and anticancer synergic action 155
MR309/E-52862, a first-in-class sigma-1 receptor antagonist, in oxaliplatin-induced peripheral neuropathy. An exploratory Phase II clinical trial 154
ACCURATE NEUROPHYSIOLOGICAL MONITORING FOR SENSORY NEUROPATHY IN MOUSE MODELS OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROTOXICITY 153
Toxic Medications in Charcot-Marie-Tooth Patients: A Systematic Review 152
Chemotherapy-induced Peripheral Neuropathy 152
EVALUATION OF THE EFFICACY OF PERIPHAGEN NEUROTROPHIN-3 EXPRESSING VECTOR FOR OXALIPLATIN INDUCED PERIPHERAL NEUROPATHY. 151
Animal Models for the Study of Human Central and Peripheral Nervous System Diseases 151
An in vivo and in vitro neurophysiological approach to acute and chronic oxaliplatin-induced peripheral neurotoxicity 150
Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. 150
Distal pain and carpal tunnel syndrome diagnosis among cashiers: a longitudinal study 148
Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale 147
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 147
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients 146
Introduction to the Italian section for young neurologists 146
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 145
Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study 145
Platinum-drugs Induced Peripheral Neurotoxicity: clinical course and preclinical evidence 144
Neurophysiological examination of dorsal sural nerve 142
Chemotherapy-induced peripheral neurotoxicity–outcome measures: the issue 142
Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity? 141
Intravenous Immunoglobulin Preparation Attenuates Pain Behaviors in a Wistar Rat Model of Bortezomib-Induced Peripheral Neuropathy 139
Chemotherapy Induced Peripheral Neurotoxicity (CIPN): neurological burden from a physician and patient point of view 139
When progressive dysphagia could be related to an “old friend” – a case report 138
Topiramate Prevents Oxaliplatin Neurotoxicity in a rat model 137
The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy. 136
Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity 136
Erratum to: Distal pain and carpal tunnel syndrome diagnosis among cashiers: a longitudinal study (Int Arch Occup Environ Health, 10.1007/s00420-017-1237-8) 134
Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity 133
Morphology meets function to unravel Oxaliplatin Induced Peripheral Neurotoxicity (OIPN) 133
EMG Recordings at Rest to Verify Axonal Hyperexcitability in a Rat Model of Oxaliplatin Induced Peripheral Neurotoxicity 133
Long-term recovery from chemotherapy-induced neuropathy following paclitaxel, ixabepilone, eribulin and vinorelbine in mice 132
NERVE EXCITABILITY TESTING IN ANIMAL MODELS OF OXALIPLATIN INDUCED PERIPHERAL NEUROTOXICITY: ION CHANNEL DYSFUNCTION AS A POSSIBLE PATHOGENETIC MECHANISM. 132
Guillain–Barré Syndrome Associated with COVID-19 132
How to assess models of oxaliplatin induced peripheral neurotoxicity – a neurophysiological translational approach 130
NERVE EXCITABILITY TESTING AS THE LINK BETWEEN ANATOMY AND PHYSIOLOGY: AXONAL EXCITABILITY TESTING TO TEST IN VIVO MECHANISMS OF PERIPHERAL NERVE DAMAGE. 130
ERIBULIN, PACLITAXEL, IXABEPILONE AND VINORELBINE-INDUCED PERIPHERAL NEUROPATHY IN MICE: INSIGHTS IN LONG-TERM RECOVERY 128
Methods for in vivo studies in rodents of chemotherapy induced peripheral neuropathy 128
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 127
Advanced neurophysiology - a translational approach to neuropathy and neuropathic pain 127
Neurofilament light chain serum levels as a possible paclitaxel-induced peripheral neurotoxicity biomarker: pilot and feasibility study. 127
Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models 126
Ivig Effect In A Wistar Rat Model Of Bortezomib-Induced Peripheral Neuropathy 126
Chemotherapy induced peripheral neurotoxicity: the search for the ideal outcome measure 126
Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neuropathy 126
Tackling Oxaliplatin Induced Peripheral neurotoxicity: from bed to bench side and back. 126
The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure 124
Responsiveness and Minimal Clinical Important Difference (MCID) of the Total Neuropathy Score clinical and nurse versions in CIPN 123
Morpho-Functional Characterisation of the Rat Ventral Caudal Nerve in a Model of Axonal Peripheral Neuropathy 122
Topiramate in Oxaliplatin-Induced Peripheral Neurotoxicity: more than neuroprotection. 122
Oxaliplatin induced peripheral neurotoxicity – a neurophysiological translational approach 120
Addressing the Need of a Translational Approach in Peripheral Neuropathy Research: Morphology Meets Function 120
Blood neurofilament light chains as a potential damage marker in chemotherapy-induce peripheral neuropathy rodent models 118
Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer 115
Neuropatie periferiche 115
Pharmacokinetics of IVIg in Wistar rats 115
Toxic neuropathies: chemotherapy induced peripheral neurotoxicity. 114
Chemotherapy-induced peripheral neurotoxicity: A multifaceted, still unsolved issue 111
Totale 16.667
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.576
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.576
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.729 0 0 0 0 363 528 586 289 336 288 267 72
2020/20213.952 184 153 439 367 290 498 470 505 305 265 172 304
2021/20222.010 147 252 179 179 171 165 79 91 112 130 174 331
2022/20233.550 434 806 333 313 272 575 78 193 251 69 121 105
2023/20243.401 112 168 174 158 389 706 623 161 240 94 95 481
2024/20253.433 449 1.032 827 426 699 0 0 0 0 0 0 0
Totale 24.376